RQx Pharmaceuticals
Stage
Acquired | AcquiredTotal Raised
$1MAbout RQx Pharmaceuticals
RQx Pharmaceuticals is a biopharmaceutical company developing broad spectrum antibiotics. The Company endeavors to optimize natural product chemical scaffolds using medicinal chemistry techniques to generate broad spectrum antibiotics. RQx is focused on a novel molecular target for which no antibiotic has been developed. Additionally, RQx has generated proprietary molecules based on a novel chemical scaffold. RQx and its technologies are a strong response to the world's growing need for new antibiotics (due to resistance) and the lack of success with small molecules over the past 20 years. The Company's initial products will focus on community and hospital associated infections, including those from gram-negative bacteria. The Company was founded based on important discoveries in Floyd Romesberg's lab at the The Scripps Research Institute in La Jolla, CA.
Missing: RQx Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: RQx Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing RQx Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
RQx Pharmaceuticals is included in 1 Expert Collection, including Regenerative Medicine.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
RQx Pharmaceuticals Patents
RQx Pharmaceuticals has filed 10 patents.
The 3 most popular patent topics include:
- Antibiotic resistance
- Antibiotics
- Cephalosporin antibiotics
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/21/2016 | 7/27/2021 | Antibiotics, Fluoroquinolone antibiotics, Piperazines, Cephalosporin antibiotics, Inflammations | Grant |
Application Date | 11/21/2016 |
|---|---|
Grant Date | 7/27/2021 |
Title | |
Related Topics | Antibiotics, Fluoroquinolone antibiotics, Piperazines, Cephalosporin antibiotics, Inflammations |
Status | Grant |
Latest RQx Pharmaceuticals News
Jun 2, 2017
LA JOLLA, Calif., Feb. 12, 2013 /PRNewswire/ -- RQx Pharmaceuticals, Inc. today announced that it has entered into a drug discovery collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for the discovery and development of novel drug compounds for an undisclosed target. Under the terms of the agreement, RQx will receive an up-front payment and is eligible to receive research and development milestone payments totaling $111 million. In addition, RQx is eligible to receive royalties on sales of products resulting from the collaboration. "We have made tremendous progress at RQx since the company's founding two years ago, and we are pleased to be moving forward in partnership with Genentech to bring new drugs to market," said Court Turner, CEO of RQx and venture partner at Avalon Ventures. RQx Pharmaceuticals was founded by Avalon Ventures in 2010 with Floyd Romesberg, Ph.D., a professor at The Scripps Research Institute (La Jolla, CA) and two former graduate students of the Romesberg Lab. Avalon Ventures formed the company, then seeded and led the Company's Series A financing, which also included an investment from Correlation Ventures. "We see a unique opportunity to apply Genentech's expertise in drug discovery and development with the innovation and focus of RQx, to develop a new class of novel drug compounds," said James Sabry, senior vice president of partnering at Genentech. About RxQ Pharmaceuticals, Inc. RQx Pharmaceuticals is a biopharmaceutical company developing broad-spectrum small molecule antibiotics to combat serious life threatening infections, including those caused by multi drug-resistant Gram-negative bacteria. To address the growing threat of MDR bacteria, RQx is developing novel, first-in-class antibiotics that evade the current abundance of antibiotic resistance mechanisms, which are now common across the globe. RQx is inspired by the synergies possible when combining naturally produced antibiotics with modern medical chemistry capabilities and is focused on identifying ideal target/inhibitor combinations to deliver a pipeline of novel antibiotic candidates. SOURCE RQx Pharmaceuticals, Inc.
RQx Pharmaceuticals Frequently Asked Questions (FAQ)
Where is RQx Pharmaceuticals's headquarters?
RQx Pharmaceuticals's headquarters is located at 11099 N. Torrey Pines Road, La Jolla.
What is RQx Pharmaceuticals's latest funding round?
RQx Pharmaceuticals's latest funding round is Acquired.
How much did RQx Pharmaceuticals raise?
RQx Pharmaceuticals raised a total of $1M.
Who are the investors of RQx Pharmaceuticals?
Investors of RQx Pharmaceuticals include Genentech, Avalon Ventures and Correlation Ventures.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.